Zentalis Pharmaceuticals, Inc. Operating Lease, Impairment Loss
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Operating Lease, Impairment Loss of $3.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseImpairmentLoss · last filed 2026-03-26
- Zentalis Pharmaceuticals, Inc. operating lease, impairment loss for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. operating lease, impairment loss for the quarter ending 2024-09-30 was $0.00.
- Zentalis Pharmaceuticals, Inc. operating lease, impairment loss for the quarter ending 2024-06-30 was -$772.00K.
- Zentalis Pharmaceuticals, Inc. operating lease, impairment loss for the quarter ending 2024-03-31 was $772.00K, a 84.41% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. operating lease, impairment loss for fiscal 2025 was $3.00M.
- Zentalis Pharmaceuticals, Inc. operating lease, impairment loss for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Zentalis Pharmaceuticals, Inc. operating lease, impairment loss for fiscal 2023 was $5.00M.
- Zentalis Pharmaceuticals, Inc. operating lease, impairment loss for fiscal 2022 was $0.00.
| Period end | Operating Lease, Impairment Loss 3 month | Operating Lease, Impairment Loss 6 month | Operating Lease, Impairment Loss 9 month | Operating Lease, Impairment Loss 12 month | Operating Lease, Impairment Loss 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $3.00M 10-K · filed 2026-03-26 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $0.00 derived: sum of 2 quarters · filed 2025-03-26 | -$772.00K derived: sum of 3 quarters · filed 2025-03-26 | $0.00 10-K · filed 2025-03-26 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$772.00K derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $47.00K derived: sum of 4 quarters · filed 2026-03-26 | |
| 2024-06-30 | -$772.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | $47.00K derived: sum of 3 quarters · filed 2026-03-26 | $47.00K derived: sum of 4 quarters · filed 2026-03-26 | |
| 2024-03-31 | $772.00K 10-Q · filed 2024-05-07 | $819.00K derived: sum of 2 quarters · filed 2026-03-26 | $819.00K derived: sum of 3 quarters · filed 2026-03-26 | $819.00K derived: sum of 4 quarters · filed 2026-03-26 | |
| 2023-12-31 | $47.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $47.00K derived: sum of 2 quarters · filed 2026-03-26 | $47.00K derived: sum of 3 quarters · filed 2026-03-26 | $5.00M 10-K · filed 2026-03-26 | $4.95M 10-K · filed 2024-02-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $4.95M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $4.95M 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | $4.95M 10-Q · filed 2024-05-07 | ||||
| 2022-12-31 | $0.00 10-K · filed 2025-03-26 | ||||
| 2021-12-31 | $0.00 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |